Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neurotherapeutics ; 18(2): 1151-1165, 2021 04.
Artigo em Inglês | MEDLINE | ID: mdl-33782863

RESUMO

Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease (MJD), is a polyglutamine expansion disease arising from a trinucleotide CAG repeat expansion in exon 10 of the gene ATXN3. There are no effective pharmacological treatments for MJD, thus the identification of new pathogenic mechanisms, and the development of novel therapeutics is urgently needed. In this study, we performed a comprehensive, blind drug screen of 3942 compounds (many FDA approved) and identified small molecules that rescued the motor-deficient phenotype in transgenic ATXN3 Caenorhabditis elegans strain. Out of this screen, five lead compounds restoring motility, protecting against neurodegeneration, and increasing the lifespan in ATXN3-CAG89 mutant worms were identified. These compounds were alfacalcidol, chenodiol, cyclophosphamide, fenbufen, and sulfaphenazole. We then investigated how these molecules might exert their neuroprotective properties. We found that three of these compounds, chenodiol, fenbufen, and sulfaphenazole, act as modulators for TFEB/HLH-30, a key transcriptional regulator of the autophagy process, and require this gene for their neuroprotective activities. These genetic-chemical approaches, using genetic C. elegans models for MJD and the screening, are promising tools to understand the mechanisms and pathways causing neurodegeneration, leading to MJD. Positively acting compounds may be promising candidates for investigation in mammalian models of MJD and preclinical applications in the treatment of this disease.


Assuntos
Ataxina-3/genética , Fatores de Transcrição de Zíper de Leucina e Hélice-Alça-Hélix Básicos/genética , Fatores de Transcrição Hélice-Alça-Hélice Básicos/genética , Proteínas de Caenorhabditis elegans/genética , Ácido Quenodesoxicólico/administração & dosagem , Fenilbutiratos/administração & dosagem , Sulfafenazol/administração & dosagem , Animais , Animais Geneticamente Modificados , Ataxina-3/toxicidade , Caenorhabditis elegans , Proteínas de Caenorhabditis elegans/toxicidade , Avaliação Pré-Clínica de Medicamentos/métodos , Longevidade/efeitos dos fármacos , Longevidade/fisiologia , Doenças Neurodegenerativas/tratamento farmacológico , Doenças Neurodegenerativas/genética
2.
Elife ; 92020 09 21.
Artigo em Inglês | MEDLINE | ID: mdl-32955441

RESUMO

Spinocerebellar ataxia type 3 (SCA3) belongs to the family of polyglutamine neurodegenerations. Each disorder stems from the abnormal lengthening of a glutamine repeat in a different protein. Although caused by a similar mutation, polyglutamine disorders are distinct, implicating non-polyglutamine regions of disease proteins as regulators of pathogenesis. SCA3 is caused by polyglutamine expansion in ataxin-3. To determine the role of ataxin-3's non-polyglutamine domains in disease, we utilized a new, allelic series of Drosophila melanogaster. We found that ataxin-3 pathogenicity is saliently controlled by polyglutamine-adjacent ubiquitin-interacting motifs (UIMs) that enhance aggregation and toxicity. UIMs function by interacting with the heat shock protein, Hsc70-4, whose reduction diminishes ataxin-3 toxicity in a UIM-dependent manner. Hsc70-4 also enhances pathogenicity of other polyglutamine proteins. Our studies provide a unique insight into the impact of ataxin-3 domains in SCA3, identify Hsc70-4 as a SCA3 enhancer, and indicate pleiotropic effects from HSP70 chaperones, which are generally thought to suppress polyglutamine degeneration.


Assuntos
Ataxina-3 , Proteínas de Drosophila/metabolismo , Proteínas de Choque Térmico HSC70/metabolismo , Peptídeos , Ubiquitina/metabolismo , Motivos de Aminoácidos , Animais , Ataxina-3/química , Ataxina-3/genética , Ataxina-3/metabolismo , Ataxina-3/toxicidade , Drosophila , Proteínas de Drosophila/química , Proteínas de Choque Térmico HSC70/química , Humanos , Larva/metabolismo , Doença de Machado-Joseph/genética , Peptídeos/química , Peptídeos/genética , Peptídeos/metabolismo , Peptídeos/toxicidade , Ubiquitina/química
3.
Neurobiol Dis ; 132: 104535, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31310802

RESUMO

The most commonly inherited dominant ataxia, Spinocerebellar Ataxia Type 3 (SCA3), is caused by a CAG repeat expansion that encodes an abnormally long polyglutamine (polyQ) repeat in the disease protein ataxin-3, a deubiquitinase. Two major full-length isoforms of ataxin-3 exist, both of which contain the same N-terminal portion and polyQ repeat, but differ in their C-termini; one (denoted here as isoform 1) contains a motif that binds ataxin-3's substrate, ubiquitin, whereas the other (denoted here as isoform 2) has a hydrophobic tail. Most SCA3 studies have focused on isoform 1, the predominant version in mammalian brain, yet both isoforms are present in brain and a better understanding of their relative pathogenicity in vivo is needed. We took advantage of the fruit fly, Drosophila melanogaster to model SCA3 and to examine the toxicity of each ataxin-3 isoform. Our assays reveal isoform 1 to be markedly more toxic than isoform 2 in all fly tissues. Reduced toxicity from isoform 2 is due to much lower protein levels as a result of its expedited degradation. Additional studies indicate that isoform 1 is more aggregation-prone than isoform 2 and that the C-terminus of isoform 2 is critical for its enhanced proteasomal degradation. According to our results, although both full-length, pathogenic ataxin-3 isoforms are toxic, isoform 1 is likely the primary contributor to SCA3 due to its presence at higher levels. Isoform 2, as a result of rapid degradation that is dictated by its tail, is unlikely to be a key player in this disease. Our findings provide new insight into the biology of this ataxia and the cellular processing of the underlying disease protein.


Assuntos
Ataxina-3/genética , Ataxina-3/toxicidade , Proteínas de Drosophila/genética , Proteínas de Drosophila/toxicidade , Doença de Machado-Joseph/genética , Proteínas Repressoras/genética , Proteínas Repressoras/toxicidade , Sequência de Aminoácidos , Animais , Animais Geneticamente Modificados , Drosophila melanogaster , Células HEK293 , Células HeLa , Humanos , Doença de Machado-Joseph/fisiopatologia , Isoformas de Proteínas/genética , Isoformas de Proteínas/toxicidade
4.
PLoS One ; 10(6): e0129727, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26052945

RESUMO

Ataxin-3 (AT3) is a deubiquitinating enzyme that triggers an inherited neurodegenerative disorder, spinocerebellar ataxia type 3, when its polyglutamine (polyQ) stretch close to the C-terminus exceeds a critical length. AT3 variants carrying the expanded polyQ are prone to associate with each other into amyloid toxic aggregates, which are responsible for neuronal death with ensuing neurodegeneration. We employed Saccharomyces cerevisiae as a eukaryotic cellular model to better clarify the mechanism by which AT3 triggers the disease. We expressed three variants: one normal (Q26), one expanded (Q85) and one truncated for a region lying from the beginning of its polyQ stretch to the end of the protein (291Δ). We found that the expression of the expanded form caused reduction in viability, accumulation of reactive oxygen species, imbalance of the antioxidant defense system and loss in cell membrane integrity, leading to necrotic death. The truncated variant also exerted a qualitatively similar, albeit milder, effect on cell growth and cytotoxicity, which points to the involvement of also non-polyQ regions in cytotoxicity. Guanidine hydrochloride, a well-known inhibitor of the chaperone Hsp104, almost completely restored wild-type survival rate of both 291Δ- and Q85-expressing strains. This suggests that AT3 aggregation and toxicity is mediated by prion forms of yeast proteins, as this chaperone plays a key role in their propagation.


Assuntos
Ataxina-3/toxicidade , Modelos Biológicos , Proteínas Mutantes/toxicidade , Saccharomyces cerevisiae/metabolismo , Antioxidantes/metabolismo , Apoptose/efeitos dos fármacos , Guanidina/farmacologia , Proteínas de Choque Térmico/metabolismo , Humanos , Chaperonas Moleculares/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Propídio/metabolismo , Agregados Proteicos/efeitos dos fármacos , Saccharomyces cerevisiae/efeitos dos fármacos , Saccharomyces cerevisiae/enzimologia , Saccharomyces cerevisiae/crescimento & desenvolvimento , Proteínas de Saccharomyces cerevisiae/metabolismo , Dodecilsulfato de Sódio/farmacologia , Solubilidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...